Skip to main content
Erschienen in: Head and Neck Pathology 2/2018

31.07.2017 | Original Paper

A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors

verfasst von: Adepitan A. Owosho, Cherry L. Estilo, Joseph M. Huryn, Ping Chi, Cristina R. Antonescu

Erschienen in: Head and Neck Pathology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Head and neck high grade malignant peripheral nerve sheath tumors (HN-MPNSTs) are rare highly aggressive soft tissue sarcomas that show overlapping morphologic and immunophenotypic features with melanoma and other high grade sarcomas, resulting in diagnostic challenges, particularly in sporadic settings. Recent discoveries have implicated loss of function mutations in the polycomb repressive complex 2 (PRC2) components, including EED or SUZ12 genes, as one of the leading pathogenetic mechanisms in high grade MPNST. MPNSTs with PRC2 loss are associated with complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3), which emerged as a reliable immunohistochemical marker in the diagnosis of sporadic and radiation induced MPNST. As the diagnosis of MPNST in the HN is particularly challenging to distinguish from melanoma and other sarcoma types, we carried out a clinicopathologic analysis on HN-MPNST patients managed at our institution over a 20-year period (1997–2016), using the latest diagnostic criteria including H3K27me3 staining and other molecular investigations. The overall survival of HN-MPNST was compared with other HN soft tissue sarcomas. The diagnosis of HN-MPNST was confirmed in 13 patients (seven males and six females), with a mean age of 31 years; with 3 (23%) patients being of pediatric age. The most common site was the neck soft tissue (77%). Two-thirds of patients (n = 9) had stigmata of NF1, three had prior radiotherapy and only one developed a de novo MPNST. All except one tumor (86%) tested showed loss of H3K27me3 expression, including all non-NF1 patients. The 2 and 5-year DSS rates were 50 and 30%. The 2-year DFS rate was 21%. Adverse predictors on DSS included adult age (p = 0.011), prior-history of RT (p = 0.003) and recurrence (p = 0.003). Compared to other molecularly confirmed subsets of HN sarcomas (Ewing and Ewing-like sarcoma, rhabdomyosarcoma and synovial sarcoma), HN-MPNST had the worst overall survival (p < 0.0001). We conclude that HN-MPNSTs are highly aggressive sarcomas associated with an unfavorable outcome and the utility of H3K27me3 IHC stains in the evaluation of MPNST is a reliable ancillary diagnostic adjunct.
Literatur
1.
Zurück zum Zitat Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO clasification of tumours of soft tissue and bone. Lyon: IARC Press; 2013. pp. 134–5. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO clasification of tumours of soft tissue and bone. Lyon: IARC Press; 2013. pp. 134–5.
2.
Zurück zum Zitat Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006–21.CrossRefPubMed Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006–21.CrossRefPubMed
3.
Zurück zum Zitat Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77–84.CrossRefPubMed Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77–84.CrossRefPubMed
4.
Zurück zum Zitat Patel TD, Shaigany K, Fang CH, Park RC, Baredes S, Eloy JA. Comparative analysis of head and neck and non-head and neck malignant peripheral nerve sheath tumors. Otolaryngology-head and neck surgery: official journal of American Academy of Otolaryngology-head and neck. Surgery. 2016;154:113–20. Patel TD, Shaigany K, Fang CH, Park RC, Baredes S, Eloy JA. Comparative analysis of head and neck and non-head and neck malignant peripheral nerve sheath tumors. Otolaryngology-head and neck surgery: official journal of American Academy of Otolaryngology-head and neck. Surgery. 2016;154:113–20.
6.
Zurück zum Zitat Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065–74.CrossRefPubMed Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065–74.CrossRefPubMed
7.
Zurück zum Zitat Hrehorovich PA, Franke HR, Maximin S, Caracta P. Malignant peripheral nerve sheath tumor. Radiogr 2003;23:790–4.CrossRef Hrehorovich PA, Franke HR, Maximin S, Caracta P. Malignant peripheral nerve sheath tumor. Radiogr 2003;23:790–4.CrossRef
8.
Zurück zum Zitat LaFemina J, Qin LX, Moraco NH, Antonescu CR, Fields RC, Crago AM, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013;20:66–72.CrossRefPubMed LaFemina J, Qin LX, Moraco NH, Antonescu CR, Fields RC, Crago AM, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013;20:66–72.CrossRefPubMed
10.
Zurück zum Zitat Vege DS, Chinoy RF, Ganesh B, Parikh DM. Malignant peripheral nerve sheath tumors of the head and neck: a clinicopathological study. J Surg Oncol. 1994;55:100–3.CrossRefPubMed Vege DS, Chinoy RF, Ganesh B, Parikh DM. Malignant peripheral nerve sheath tumors of the head and neck: a clinicopathological study. J Surg Oncol. 1994;55:100–3.CrossRefPubMed
11.
Zurück zum Zitat D’Agostino AN, Soule EH, Miller RH. Primary malignant neoplasms of nerves (malignant neurilemomas) in patients without manifestations of multiple neurofibromatosis (Von Recklinghausen’s disease). Cancer. 1963;16:1003–14.CrossRefPubMed D’Agostino AN, Soule EH, Miller RH. Primary malignant neoplasms of nerves (malignant neurilemomas) in patients without manifestations of multiple neurofibromatosis (Von Recklinghausen’s disease). Cancer. 1963;16:1003–14.CrossRefPubMed
12.
Zurück zum Zitat Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. 2009;2009:756395.CrossRefPubMedPubMedCentral Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. 2009;2009:756395.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42:351–60.CrossRefPubMed Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42:351–60.CrossRefPubMed
14.
Zurück zum Zitat deCou JM, Rao BN, Parham DM, Lobe TE, Bowman L, Pappo AS, et al. Malignant peripheral nerve sheath tumors: the St. Jude Children’s Research Hospital experience. Ann Surg Oncol. 1995;2:524–9.CrossRefPubMed deCou JM, Rao BN, Parham DM, Lobe TE, Bowman L, Pappo AS, et al. Malignant peripheral nerve sheath tumors: the St. Jude Children’s Research Hospital experience. Ann Surg Oncol. 1995;2:524–9.CrossRefPubMed
15.
Zurück zum Zitat Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014–22.CrossRefPubMed Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014–22.CrossRefPubMed
16.
Zurück zum Zitat Ma C, Ow A, Shan OH, Wu Y, Zhang C, Sun J, et al. Malignant peripheral nerve sheath tumours in the head and neck region: retrospective analysis of clinicopathological features and treatment outcomes. Int J Oral Maxillofac Surg. 2014;43:924–32.CrossRefPubMed Ma C, Ow A, Shan OH, Wu Y, Zhang C, Sun J, et al. Malignant peripheral nerve sheath tumours in the head and neck region: retrospective analysis of clinicopathological features and treatment outcomes. Int J Oral Maxillofac Surg. 2014;43:924–32.CrossRefPubMed
17.
Zurück zum Zitat Arshi A, Tajudeen BA, St John M. Malignant peripheral nerve sheath tumors of the head and neck: demographics, clinicopathologic features, management, and treatment outcomes. Oral Oncol. 2015;51:1088–94.CrossRefPubMed Arshi A, Tajudeen BA, St John M. Malignant peripheral nerve sheath tumors of the head and neck: demographics, clinicopathologic features, management, and treatment outcomes. Oral Oncol. 2015;51:1088–94.CrossRefPubMed
18.
Zurück zum Zitat Minovi A, Basten O, Hunter B, Draf W, Bockmuhl U. Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck. 2007;29:439–45.CrossRefPubMed Minovi A, Basten O, Hunter B, Draf W, Bockmuhl U. Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck. 2007;29:439–45.CrossRefPubMed
19.
Zurück zum Zitat Bahrami A, Folpe AL. Adult-type fibrosarcoma: a reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol. 2010;34:1504–13.CrossRefPubMed Bahrami A, Folpe AL. Adult-type fibrosarcoma: a reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol. 2010;34:1504–13.CrossRefPubMed
20.
Zurück zum Zitat Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123:295–319.CrossRefPubMedPubMedCentral Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123:295–319.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol. 2008;35:1014–9.CrossRefPubMed Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol. 2008;35:1014–9.CrossRefPubMed
22.
Zurück zum Zitat Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32:1291–8.CrossRefPubMed Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32:1291–8.CrossRefPubMed
23.
Zurück zum Zitat Karamchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20:445–50.CrossRefPubMed Karamchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20:445–50.CrossRefPubMed
24.
Zurück zum Zitat Miettinen M, McCue PA, Sarlomo-Rikala M, Biernat W, Czapiewski P, Kopczynski J, et al. Sox10–a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors. Am J Surg Pathol. 2015;39:826–35.CrossRefPubMedPubMedCentral Miettinen M, McCue PA, Sarlomo-Rikala M, Biernat W, Czapiewski P, Kopczynski J, et al. Sox10–a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors. Am J Surg Pathol. 2015;39:826–35.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, et al. Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. Am J Surg Pathol. 2009;33:325–38.CrossRefPubMed Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, et al. Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. Am J Surg Pathol. 2009;33:325–38.CrossRefPubMed
26.
Zurück zum Zitat Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227–32.CrossRefPubMedPubMedCentral Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227–32.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1170–2.CrossRefPubMedPubMedCentral Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1170–2.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247–51.CrossRefPubMed De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247–51.CrossRefPubMed
29.
Zurück zum Zitat Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol. 2016;40:479–89.CrossRefPubMedPubMedCentral Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol. 2016;40:479–89.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29:582–90.CrossRefPubMedPubMedCentral Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29:582–90.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Owosho AA, Estilo CL, Huryn JM, Zhang L, Fletcher CD, Antonescu CR. Head and neck round cell sarcomas: a comparative clinicopathologic analysis of 2 molecular subsets: ewing and CIC-rearranged sarcomas. Head Neck Pathol. 2017. doi:10.1007/s12105-017-0808-2. Owosho AA, Estilo CL, Huryn JM, Zhang L, Fletcher CD, Antonescu CR. Head and neck round cell sarcomas: a comparative clinicopathologic analysis of 2 molecular subsets: ewing and CIC-rearranged sarcomas. Head Neck Pathol. 2017. doi:10.​1007/​s12105-017-0808-2.
32.
Zurück zum Zitat Antonescu CR, Owosho AA, Zhang L, Chen S, Deniz K, Huryn JM, et al. Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol. 2017;41:941–49. Antonescu CR, Owosho AA, Zhang L, Chen S, Deniz K, Huryn JM, et al. Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases. Am J Surg Pathol. 2017;41:941–49.
33.
Zurück zum Zitat Owosho AA, Huang SC, Chen S, Kashikar S, Estilo CL, Wolden SL, et al. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome. Oral Oncol. 2016;61:89–97.CrossRefPubMedCentral Owosho AA, Huang SC, Chen S, Kashikar S, Estilo CL, Wolden SL, et al. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome. Oral Oncol. 2016;61:89–97.CrossRefPubMedCentral
34.
Zurück zum Zitat Owosho AA, Chen S, Kashikar S, Zhang L, Chen CL, Wexler LH, et al. Clinical and molecular heterogeneity of head and neck spindle cell and sclerosing rhabdomyosarcoma. Oral Oncol. 2016;58:e6–11.CrossRefPubMedPubMedCentral Owosho AA, Chen S, Kashikar S, Zhang L, Chen CL, Wexler LH, et al. Clinical and molecular heterogeneity of head and neck spindle cell and sclerosing rhabdomyosarcoma. Oral Oncol. 2016;58:e6–11.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Owosho AA, Estilo CL, Rosen EB, Yom SK, Huryn JM, Antonescu CR. A clinicopathologic study on SS18 fusion positive head and neck synovial sarcomas. Oral Oncol. 2017;66:46–51.CrossRefPubMedPubMedCentral Owosho AA, Estilo CL, Rosen EB, Yom SK, Huryn JM, Antonescu CR. A clinicopathologic study on SS18 fusion positive head and neck synovial sarcomas. Oral Oncol. 2017;66:46–51.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Rohrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016;131:877–87.CrossRefPubMed Rohrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016;131:877–87.CrossRefPubMed
37.
Zurück zum Zitat Asano N, Yoshida A, Ichikawa H, Mori T, Nakamura M, Kawai A, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology. 2017;70:385–93.CrossRefPubMed Asano N, Yoshida A, Ichikawa H, Mori T, Nakamura M, Kawai A, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology. 2017;70:385–93.CrossRefPubMed
38.
Zurück zum Zitat Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29:4–13.CrossRefPubMed Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29:4–13.CrossRefPubMed
39.
Zurück zum Zitat Pasmant E, Sohier P, Larousserie F. Synovial sarcomas do not show H3K27 trimethylation loss using immunohistochemistry. Am J Surg Pathol. 2017;41:283–5.CrossRefPubMed Pasmant E, Sohier P, Larousserie F. Synovial sarcomas do not show H3K27 trimethylation loss using immunohistochemistry. Am J Surg Pathol. 2017;41:283–5.CrossRefPubMed
40.
Zurück zum Zitat Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol. 2010;28:2064–9.CrossRefPubMedPubMedCentral Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol. 2010;28:2064–9.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Bishop AJ, Zagars GK, Torres KE, Bird JE, Feig BW, Guadagnolo BA. Malignant peripheral nerve sheath tumors: a single institution’s experience using combined surgery and radiation therapy. Am J Clin Oncol. 2016. doi:10.1097/COC.0000000000000303. Bishop AJ, Zagars GK, Torres KE, Bird JE, Feig BW, Guadagnolo BA. Malignant peripheral nerve sheath tumors: a single institution’s experience using combined surgery and radiation therapy. Am J Clin Oncol. 2016. doi:10.​1097/​COC.​0000000000000303​.
42.
Zurück zum Zitat Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJ, Van Glabbeke M, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol. 2011;22:207–14.CrossRefPubMed Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJ, Van Glabbeke M, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol. 2011;22:207–14.CrossRefPubMed
Metadaten
Titel
A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors
verfasst von
Adepitan A. Owosho
Cherry L. Estilo
Joseph M. Huryn
Ping Chi
Cristina R. Antonescu
Publikationsdatum
31.07.2017
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 2/2018
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-017-0841-y

Weitere Artikel der Ausgabe 2/2018

Head and Neck Pathology 2/2018 Zur Ausgabe

Sine qua non Clinicopathologic Correlation

Large Cell Transformation of Oral Mycosis Fungoides

Neu im Fachgebiet Pathologie